In addition, EGFR gene mutations have been reported in patients with non-small-cell lung cancer, and the status of these mutations has been correlated with the clinical response to tyrosine kinase inhibitors such as gefitinib[23]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.